Biogen Inc. (BIIB) Earnings History
Annual and quarterly earnings data from 1989 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 70.5% | 19.1% | 13.2% |
| 2024 | 76.1% | 25.7% | 16.9% |
| 2023 | 74.2% | 21.3% | 11.8% |
| 2022 | 77.6% | 28.4% | 29.9% |
| 2021 | 80.8% | 25.4% | 14.2% |
Download Data
Export BIIB earnings history in CSV or JSON format
Free sign-in required to download data
Biogen Inc. (BIIB) Earnings Overview
As of February 28, 2026, Biogen Inc. (BIIB) reported trailing twelve-month net income of $1.29B, reflecting -0.2% year-over-year growth. The company earned $8.82 per diluted share over the past four quarters, with a net profit margin of 0.1%.
Looking at the long-term picture, BIIB's 5-year EPS compound annual growth rate (CAGR) stands at -18.7%, signaling declining earnings. The company achieved its highest annual net income of $5.89B in fiscal 2019.
Biogen Inc. maintains positive profitability with a gross margin of 0.7%, operating margin of 0.2%, and net margin of 0.1%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including ABBV ($2.39B net income, 0.1% margin), AMGN ($7.71B net income, 0.2% margin), GILD ($8.51B net income, 0.0% margin), BIIB has outperformed on profitability metrics. Compare BIIB vs ABBV →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
37 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.29B | -20.8% | $1.88B | $8.83 | 13.2% | 19.1% |
| 2024 | $1.63B | +40.6% | $2.49B | $11.19 | 16.9% | 25.7% |
| 2023 | $1.16B | -61.9% | $2.10B | $7.97 | 11.8% | 21.3% |
| 2022 | $3.05B | +95.8% | $2.89B | $20.87 | 29.9% | 28.4% |
| 2021 | $1.56B | -61.1% | $2.79B | $10.40 | 14.2% | 25.4% |
| 2020 | $4.00B | -32.1% | $4.59B | $24.80 | 29.8% | 34.2% |
| 2019 | $5.89B | +32.9% | $7.04B | $31.42 | 41.0% | 49.0% |
| 2018 | $4.43B | +74.5% | $5.89B | $21.58 | 32.9% | 43.8% |
| 2017 | $2.54B | -31.4% | $5.35B | $11.92 | 20.7% | 43.6% |
| 2016 | $3.70B | +4.4% | $5.15B | $16.93 | 32.3% | 45.0% |
See BIIB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BIIB Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare BIIB vs AGIO
See how BIIB stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is BIIB growing earnings?
BIIB EPS of $8.82 reflects slowing growth at -0.2%, below the 5-year CAGR of -18.7%. TTM net income is $1.3B. Expansion rate has moderated.
What are BIIB's profit margins?
Biogen Inc. net margin is +0.1%, with operating margin at +0.2%. Below-average margins reflect competitive or cost pressures.
How consistent are BIIB's earnings?
BIIB earnings data spans 1989-2025. The current earnings trend is -0.2% YoY. Historical data enables comparison across business cycles.